Evolving pattern with age of cutaneous signs in neurofibromatosis type 1: A cross-sectional study of 728 patients

Dermatology

Volumn 222, Issue 3, 2011, Pages 269-273

  Duong, T A ^a   Bastuji Garin, S ^b,c   Valeyrie Allanore, L ^a,b,c   Sbidian, E ^b   Ferkal, S ^b   Wolkenstein, P ^a,b,c  

^a HENRI MONDOR HOSPITAL   (France)

^b UNIVERSITÉ PARIS EST   (France)

^c FACULTÉ DE MÉDECINE   (France)

Author keywords

Caf au lait spot; Cutaneous manifestations; Neurofibromas; Neurofibromatosis type 1

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL FEATURE; FEMALE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROFIBROMATOSIS; PHENOTYPE; PREGNANCY; PRESCHOOL CHILD; PRIORITY JOURNAL; PUBERTY; SCHOOL CHILD; SKIN TUMOR;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CAFE-AU-LAIT SPOTS; CHILD; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROFIBROMA; NEUROFIBROMATOSIS 1; PREVALENCE; SKIN NEOPLASMS; YOUNG ADULT;

EID: 79960020616     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000327379     Document Type: Article

References (21)

1. Huson SM, Harper PS, Compston DA: Von Recklinghausen neurofibromatosis: a clini-cal and population study in south-east Wales. Brain 1988; 111:1355-1381. (Pubitemid 19028458)
2. National Institutes of Health Consensus De-velopment Conference Statement: neurofi-bromatosis. Bethesda, Md., USA July 13-15 1987. Neurofibromatosis 1988; 1: 172-178.
3. Friedman JM, Birch PH: Type 1 neurofibro-matosis: a descriptive analysis of the disorder in 1,728 patients. Am J Med Genet 1997; 70: 138-143. (Pubitemid 27184570)
4. Barbarot S, Nicol C, Volteau C, Le Forestier D, N'Guyen JM, Mansat E, Wolkenstein P, Stalder JF: Cutaneous lesions in neurofibro-matosis 1: confused terminology. Br J Dermatol 2007; 157: 183-184. (Pubitemid 46934245)
5. De Bella K, Szudek J, Friedman JM: Use of the National Institutes of Health criteria for diagnosis of neurofibromatosis 1 in children. Pediatrics 2000; 105:608-614. (Pubitemid 30129679)
6. Bonnemaison E, Roze-Abert B, Lorette G, Sirinelli D, Boscq M, Mazjoub S, De Courti vron B, Bonnard C, Despert F, Toutain A, Maheut-Lourmière J, Barthez MA, Castel-nau P, Réseau NF1 Tours-région Centre: Neurofibromatosis type 1 complications in the pediatric age: follow-up of a hundred cases. Arch Pediatr 2006; 13: 1009-1014.
7. Roth TM, Petty EM, Barald KF: The role of steroid hormones in the NF1 phenotype: fo-cus on pregnancy. Am J Med Genet A 2008; 146A:1624-1633. (Pubitemid 351792414)
8. Cunha KS, Barboza EP, Da Fonseca EC Identification of growth hormone receptor in localised neurofibromas of patients with neurofibromatosis type 1. J Clin Pathol 2003; 56: 758-763. (Pubitemid 37243935)
9. Overdiek A, Winner U, Mayatepek E, Rosen-baum T: Schwann cells from human neuro-fibromas show increased proliferation rates under the influence of progesterone. Pediatr Res 2008; 64:40-43.
10. Fishbein L, Zhang X, Fisher LB, Li H, Camp-bell-Thompson M, Yachnis A, Rubenstein A, Muir D, Wallace MR: In vitro studies of ste-roid hormones in neurofibromatosis 1 tu-mors and Schwann cells. Mol Carcinog 2007; 46: 512-523. (Pubitemid 47068070)
11. Sbidian E, Wolkenstein P, Valeyrie-Allanore L, Rodriguez D, Hadj-Rabia S, Ferkal S, Lacour JP, Leonard JC, Taillandier L, Spor-tich S, Berbis P, Bastuji-Garin S, members of NF France Network: NF-1 score: a prediction score for internal neurofibromas in neurofi-bromatosis-1. J Invest Dermatol 2010; 130: 2173-2178.
12. Tucker T, Wolkenstein P, Revuz J, Zeller J, Friedman JM: Association between benign and malignant peripheral nerve sheath tu-mors in NF1. Neurology 2005; 65:205-211. (Pubitemid 41022362)
13. Riccardi VM: Diagnostic and management considerations posed by multiple café au lait spots. Arch Dermatol 2009; 145: 929-930.
14. De Schepper S, Boucneau J, Lambert J, Mes-siaen L, Naeyaert JM: Pigment cell-related manifestations in neurofibromatosis type 1: an overview. Pigment Cell Res 2005; 18: 13-24. (Pubitemid 40170601)
15. De Schepper S, Boucneau J, Van der Haeghen Y, Messiaen L, Naeyaert JM, Lambert J: Café-au-lait spots in neurofibromatosis type 1 and in healthy control individuals: hyperpig-mentation of a different kind? Arch Dermatol Res 2006; 297:439-449.
16. Okazaki M, Yoshimura K, Suzuki Y, Uchida G, Kitano Y, Harii K, Imokawa G: The mech-anism of epidermal hyperpigmentation in café-au-lait macules of neurofibromatosis type 1 (von Recklinghausen's disease) may be associated with dermal fibroblast-derived stem cell factor and hepatocyte growth factor. Br J Dermatol 2003; 148:689-697. (Pubitemid 36629746)
17. Okazaki M, Yoshimura K, Harii K: Correla-tion between age and secretions of melano-cyte-stimulating cytokines in cultured kera-tinocytes and fibroblasts. Br J Dermatol 2005; 153: 23-29.
18. Ortonne JP: Pigmentary changes of the age-ing skin. Br J Dermatol 1990; 122:21-28.
19. Nunley KS, Gao F, Albers AC, Bayliss SJ, Gutmann DH: Predictive value of café au lait macules at initial consultation in the diagno-sis of neurofibromatosis type 1. Arch Derma-tol 2009; 145:883-887.
20. Korf BR: Diagnostic outcome in children with multiple café au lait spots. Pediatrics 1992; 90: 924-927.
21. Brems H, Chmara M, Sahbatou M, Denayer E, Taniguchi K, Kato R, Somers R, Messiaen L, De Schepper S, Fryns JP, Cools J, Marynen P, Thomas G, Yoshimura A, Legius E: Germ-line loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nat Genet 2007; 39:1120-1126. (Pubitemid 47340658)